On November 5, 2019, Acorda Therapeutics, Inc. (NASDAQ:ACOR) announced that it has received FDA approval for INBRIJA, an on-demand Parkinson's drug.  According to the company's press release announcing the FDA's approval of the drug, which is subject to approval by the U.S. District Court for the Southern District of New York, approximately 66% of physicians have prescribed INBRIJA to patients with Parkinson's disease.  According to the company's press release, the FDA approved INBRIJA in October 2019.  As part of the regulatory restructuring, Acorda agreed to pay approximately $20 million to settle the pending litigation.  The settlement is subject to court approval.  The SEC's complaint, filed in federal court in New York, charges Acorda with violations of the antifraud provisions of Section 17(a) of the Securities Act of 1933 and Section 10(b) of the Securities Exchange Act of 1934 and Rule 10b-5 thereunder.  Without admitting or denying the allegations in the SEC's complaint, Acorda has agreed to settle the litigation without admitting or denying the allegations in the complaint. The settlement is subject to court approval.  In a parallel action, the U.S. Attorney's Office for the Southern District of New York today announced criminal charges against Acorda.  The SEC's continuing investigation is being conducted by Michael Yee and Kenneth Atkins, and the litigation is being led by Ron Cohen.  The SEC appreciates the assistance of the U.S. Attorney's Office for New York and the Federal Bureau of Investigation.  The SEC's Office of Investor Education and Advocacy has issued anÂ Investor AlertÂ to encourage investors to check the background of anyone selling or offering them an investment using the free and simple search tool onÂ Investor.gov.